Health Trials

HR+/HER2- Ductal and Lobular Breast Cancer

2

Review clinical trials related to HR+/HER2- Ductal and Lobular Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Participants needed: 162
Trial details
Phase: Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 29, 2026Locations: 29
Eligibility criteria

Age ≥ 18 years old [+6]

Absolute neutrophil count (ANC) < 1.5 x 10^9/L, hemoglobin < 9 g/dL, or platelet... [+4]

Read more
Status: Recruiting

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Participants needed: 180
Trial details
Phase: Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jun 17, 2026Locations: 8
Eligibility criteria

Locally advanced unresectable or metastatic PDAC, with disease progression follo... [+6]

Absolute neutrophil count (ANC) < 1.5 x 109/L, hemoglobin < 9 g/dL, or platelet... [+6]

Read more